Search

Displaying results 1151 - 1160 of 9314 in total
  1. Drug

    Dihydro-alpha-ergocryptine

    go.drugbank.com/drugs/DB11274
    Approved

    Alpha-dihydroergocryptine is usually referred to the mixture of the alpha and beta dihydroergocryptine. These two compounds are differentiated in the position of a methyl group. … To know more about this mixture, please visit [DB01049]

  2. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63934] The FDA approved centanafadine on July 24, 2026, for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg; use is not recommended below that … [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Pixantrone

    go.drugbank.com/drugs/DB06193
    ApprovedWithdrawn

    However, it is notable that the EXTEND trial was stopped early, leaving the statistical significance of the results in question. … Pixantrone does not bind iron and promotes the formation of reactive oxygen species to a lesser degree than other anthracyclines.

  4. Drug

    Bendroflumethiazide

    go.drugbank.com/drugs/DB00436
    ApprovedInvestigational

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) … A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders.

  5. Drug

    Propylthiouracil

    go.drugbank.com/drugs/DB00550
    Approved

    Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. … (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)

  6. Drug

    Amlexanox

    go.drugbank.com/drugs/DB01025
    ApprovedWithdrawn

    Recurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population.

  7. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    [L53798] Later the same year, it was approved in the US for the same indication. [L54216] … [A274198] On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause.

  8. Drug

    Evening primrose oil

    go.drugbank.com/drugs/DB11358
    ApprovedNutraceutical

    [A33131] Evening primrose oil has been filled for the FDA by Humanetics Corporation on April 2000 to be a new dietary ingredient but its current status is "Inadequate basis for expectation of safety". … [L2845] By Health Canada, evening primrose oil is approved in over-the-counter combination dietary supplements.[L1113] By the EMA, evening primrose oil is approved in herbal preparations.[L2851]

    Mixtures: PRIM E CAPSULE, Evening Primrose Oil With Vitamin E
  9. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    [A237550, A237560] Fexinidazole, which was originally developed in the 1970s/80s by Hoechst AG and subsequently rediscovered through the Drugs for Neglected Diseases Initiative (DNDi) in 2005, is the first … [A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021.

  10. Drug

    Goserelin

    go.drugbank.com/drugs/DB00014
    ApprovedInvestigational

    In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. … In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells.